期刊文献+

蛋白激酶Cp选择性抑制剂Enzastaurin的特性及其在淋巴瘤治疗上的应用

原文传递
导出
摘要 Enzastaurin(LY317615)是一种口服的,选择性作用于丝/苏氨酸蛋白激酶的一种强效抑制剂。因为与B型蛋白激酶C共同竞争三磷酸腺苷,它最初作为一种可抗血管形成的PKC13(蛋白激酶C亚型B异构体)抑制剂进行早期开发研究^[1]。
作者 张晓青
出处 《中华医学杂志》 CAS CSCD 北大核心 2009年第25期1794-1796,共3页 National Medical Journal of China
  • 相关文献

参考文献41

  • 1Graft JR,McNulty AM,Hanna KR,et al.The protein Kinese Cbeta-selective inhibitor,Enzastaurin (LY317615.HCI),suppress signaling through the AKT pathway,induces apoptosis,and suppresses xenografta.Cancer Res,2005,65:7462-7469.
  • 2Hanauske AR,Eismenn U,Oberschmidt O,et al.Correlations of mRNA expression and in vitro chemosensitivity to Enzastaurin in freshly explanted human tumor cells.Invest New Drugs,2008,26:215-222.
  • 3Ma S,Rosen ST.Enzastaurin.Curt {3pin Oncol,2007,19:590-595.
  • 4Mellor H,Parker PJ.The extended protein kinase C suprefamily.Biochem J,1998,332:281-292.
  • 5Goekjian PC,,Jirousek MR.Protein kinase C inhibitors as novel anficancer drugs.Expert Opin Investig Drugs,2001,10:2117-2140.
  • 6da Rocha AB,Marts DR,Regner A,et al.Targeting protein kinase C:new therapeutic opportunities against high-grade malignant gliomas? Oncologist,2002,7:17-33.
  • 7Nishizuka Y.Discovery and prospect of protein kinase C research:epilogue.J Biochem,2003,133:155-158.
  • 8Aeder SE,Martin PM,Sob JW,et al.PKC-beta mediates glioblastoma cell proliferation through the Akt and roTOR signaling pathways.Oncegene,2004,23:9062-9069.
  • 9Gokmen-Polar Y,Murray NR,Velasco MA,et al.Elevated protein kinase C beta Ⅱ is an early promotive event in colon carcinogenesis.Cancer Res,2001,61:1375-1381.
  • 10Aref S,Mabed M,Zalata K,et al.The interplay between c-Myconcegene expression and circulating vascular endothelial growth factor (sVEGF),its antngonist receptor,soluble Flt-1 in diffuse large B cell lymphoma (DLBCL):relationship to patient outcome.Leuk Lymphoma,2004,45:499-506.

二级参考文献7

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部